NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer

Launched by DU JUAN · Jul 2, 2024

Keywords

ClinConnect Summary

This clinical trial is testing two different treatment options for patients with locally advanced pancreatic cancer, a type of cancer that has spread but is still localized. The study compares a treatment called NALIRIFOX combined with a type of immunotherapy known as PD-1 with another treatment called AG, also combined with PD-1. The goal is to find out which combination works better and is safer for patients as their first line of treatment.

To participate in this trial, patients should have a confirmed diagnosis of pancreatic cancer and be in reasonably good health, meaning they can perform daily activities with some limitations. They should not have received any prior cancer treatments and must be able to provide written consent to join the study. Participants can expect to receive close monitoring during the trial, and their health will be regularly assessed to see how well the treatments are working and if they are experiencing any side effects. This trial is currently recruiting patients aged 65 to 74, and it is important to note that those with certain medical conditions, such as severe infections or autoimmune diseases, may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically or cytologically confirmed pancreatic cancer;
• • 2. ECOG performance no more than 2;
• • 3. Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines;
• • 4. No previous anti-tumor therapy；
• • 5. Able and willing to provide a written informed consent;
• Exclusion Criteria:
• • 1. Prior anti-tumor therapy of any kind; 2. Severe infection (\>NCI CTC grade 2); 3.Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs; 4.Patients with bleeding tendency; 5. Pregnant or lactating women.